Literature DB >> 17446099

Inflammation and response to steroid treatment in limb-girdle muscular dystrophy 2I.

N Darin1, A-K Kroksmark, A-C Ahlander, A-R Moslemi, A Oldfors, M Tulinius.   

Abstract

Limb-girdle muscular dystrophy (LGMD) type 2I, caused by mutations in the fukutin-related protein gene (FKRP), is one of the most common forms of LGMD in childhood. We describe two patients with LGMD2I and a Duchenne-like phenotype. In addition to the common L276I mutation, both patients had a new mutation in FKRP, L169P and P89L, respectively. Clinical onset was triggered by viral upper respiratory tract infections. In addition to the common dystrophic pattern with a weak immune histochemical staining for alpha-dystroglycan, muscle biopsy showed inflammatory changes. This was especially striking in one of the patients with up-regulation of MHC class 1 antigen, suggestive of myositis. Both patients showed a good clinical response to treatment with prednisolone, which was initiated at daily dosage of 0.35 mg/kg/day. Our results provide evidence for an inflammatory involvement in the pathological expression of LGMD2I and open up the possibility that this disorder could be treatable with corticosteroids.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17446099     DOI: 10.1016/j.ejpn.2007.02.018

Source DB:  PubMed          Journal:  Eur J Paediatr Neurol        ISSN: 1090-3798            Impact factor:   3.140


  20 in total

1.  FKRP mutations, including a founder mutation, cause phenotype variability in Chinese patients with dystroglycanopathies.

Authors:  Xiaona Fu; Haipo Yang; Cuijie Wei; Hui Jiao; Shuo Wang; Yanling Yang; Chunxi Han; Xiru Wu; Hui Xiong
Journal:  J Hum Genet       Date:  2016-07-21       Impact factor: 3.172

2.  A limb-girdle muscular dystrophy 2I model of muscular dystrophy identifies corrective drug compounds for dystroglycanopathies.

Authors:  Peter R Serafini; Michael J Feyder; Rylie M Hightower; Daniela Garcia-Perez; Natássia M Vieira; Angela Lek; Devin E Gibbs; Omar Moukha-Chafiq; Corinne E Augelli-Szafran; Genri Kawahara; Jeffrey J Widrick; Louis M Kunkel; Matthew S Alexander
Journal:  JCI Insight       Date:  2018-09-20

Review 3.  [Standard treatment for myositis and muscular dystrophies].

Authors:  J Schmidt; M Vorgerd
Journal:  Nervenarzt       Date:  2011-06       Impact factor: 1.214

4.  Intermittent Glucocorticoid Dosing Improves Muscle Repair and Function in Mice with Limb-Girdle Muscular Dystrophy.

Authors:  Mattia Quattrocelli; Isabella M Salamone; Patrick G Page; James L Warner; Alexis R Demonbreun; Elizabeth M McNally
Journal:  Am J Pathol       Date:  2017-08-18       Impact factor: 4.307

Review 5.  Molecular Therapies for Muscular Dystrophies.

Authors:  Ava Y Lin; Leo H Wang
Journal:  Curr Treat Options Neurol       Date:  2018-06-21       Impact factor: 3.598

Review 6.  Limb-girdle and congenital muscular dystrophies: current diagnostics, management, and emerging technologies.

Authors:  Carolina Tesi Rocha; Eric P Hoffman
Journal:  Curr Neurol Neurosci Rep       Date:  2010-07       Impact factor: 5.081

Review 7.  Inclusion-body myositis: muscle-fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer's and Parkinson's disease brains.

Authors:  Valerie Askanas; W King Engel
Journal:  Acta Neuropathol       Date:  2008-10-31       Impact factor: 17.088

Review 8.  Therapeutic possibilities in the autosomal recessive limb-girdle muscular dystrophies.

Authors:  Volker Straub; Kate Bushby
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

9.  Novel compounds for the treatment of Duchenne muscular dystrophy: emerging therapeutic agents.

Authors:  Steve D Wilton; Sue Fletcher
Journal:  Appl Clin Genet       Date:  2011-03-10

Review 10.  Limb-girdle muscular dystrophies: where next after six decades from the first proposal (Review).

Authors:  Omar A Mahmood; Xin Mei Jiang
Journal:  Mol Med Rep       Date:  2014-03-13       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.